Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05554094 · ClinicalTrials.gov registry record · Phase 2
Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder
A Phase 2 study of PTSD and Stress Disorders, Post-Traumatic, sponsored by Ohio State University.
- Active
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05554094 is a Phase 2 study of PTSD and Stress Disorders, Post-Traumatic that is active but no longer recruiting, run by Ohio State University. The registered enrollment target is 15 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05554094, a Phase 2 study of PTSD and Stress Disorders, Post-Traumatic, is active but no longer recruiting, sponsored by Ohio State University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this study is to assess the safety and efficacy of psilocybin-assisted therapy in the treatment of post-traumatic stress disorder in United States military Veterans.
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
Ohio
- Ohio State University Department of Psychiatry and Behavioral Health at the Davis Medical Research Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05554094
The ClinicalTrials.gov registry entry for NCT05554094 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (95% lower). The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with PTSD appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT05554094 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05554094 about?
NCT05554094 is a clinical study titled "Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder". The primary aim of this study is to assess the safety and efficacy of psilocybin-assisted therapy in the treatment of post-traumatic stress disorder in United States military Veterans.
What is the current status of trial NCT05554094?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2023-01-01. Estimated completion is 2026-07-31.
What conditions does trial NCT05554094 study?
This clinical trial studies the following conditions: PTSD, Stress Disorders, Post-Traumatic, Mental Disorder, Trauma and Stressor Related Disorders, Stress Disorders, Traumatic.
What interventions are being tested in trial NCT05554094?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05554094?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05554094 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oxytocin to Enhance Integrated Treatment for AUD and PTSD
RECRUITING · Phase 2
-
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
RECRUITING · Phase 2
-
Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Induction of Dreaming With EEG and Anesthesia for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.